XML Feed for RxPG News   Add RxPG News Headlines to My Yahoo!   Javascript Syndication for RxPG News

Research Health World General
 
  Home
 
 Latest Research
 Cancer
 Psychiatry
 Genetics
 Surgery
 Aging
 Ophthalmology
 Gynaecology
 Neurosciences
 Pharmacology
 Cardiology
 Obstetrics
 Infectious Diseases
 Respiratory Medicine
 Pathology
 Endocrinology
 Immunology
 Nephrology
 Gastroenterology
 Biotechnology
 Radiology
 Dermatology
 Microbiology
 Haematology
 Dental
 ENT
 Environment
 Embryology
 Orthopedics
 Metabolism
 Anaethesia
 Paediatrics
 Public Health
 Urology
 Musculoskeletal
 Clinical Trials
 Physiology
 Biochemistry
 Cytology
 Traumatology
 Rheumatology
 
 Medical News
 Health
 Opinion
 Healthcare
  UK
   NHS
  USA
  World
  India
  South Africa
  New Zealand
  Australia
  Canada Healthcare
  China Healthcare
  Africa
 Professionals
 Launch
 Awards & Prizes
 
 Careers
 Medical
 Nursing
 Dental
 
 Special Topics
 Euthanasia
 Ethics
 Evolution
 Odd Medical News
 Feature
 
 World News
 Tsunami
 Epidemics
 Climate
 Business
 
 India
Search

Last Updated: Nov 18, 2006 - 12:32:53 PM

UK Channel
subscribe to UK newsletter

Medical News : Healthcare : UK

   DISCUSS   |   EMAIL   |   PRINT
NICE issues draft guidance on Trastuzumab
Jun 10, 2006 - 5:15:00 PM, Reviewed by: Dr. Priya Saxena

�These proposals are very good news for women with HER2 positive breast cancer. Herceptin, for these women is clinically and cost effective in the early stage of the disease and we look forward to being able to issue final guidance, subject to any appeal against our recommendations, in a few weeks time.�

 
NICE has published draft guidance on Herceptin, just two weeks after the drug was licensed by the regulatory authorities for use in early breast cancer. The draft guidance recommends the drug for women with early stage HER2-positive breast cancer, except where there are concerns about the woman�s cardiac function. Final guidance is expected to be issued at the beginning of July 2006, assuming there are no appeals.

NICE Chief Executive Andrew Dillon said: �These proposals are very good news for women with HER2 positive breast cancer. Herceptin, for these women is clinically and cost effective in the early stage of the disease and we look forward to being able to issue final guidance, subject to any appeal against our recommendations, in a few weeks time.�

The draft recommendations by NICE are:

1.1 Trastuzumab, given at 3-week intervals for 1 year or until disease recurrence (whichever is the shorter period), is recommended as a treatment option for women with early-stage HER2-positive breast cancer following surgery, chemotherapy (neoadjuvant or adjuvant) and radiotherapy (if applicable).

1.2 Cardiac function should be assessed prior to the commencement of therapy and trastuzumab treatment should not be offered to women who have a left ventricular ejection fraction (LVEF) of 55% or less, or who have any of the following:
� a history of documented congestive heart failure
� high-risk uncontrolled arrhythmias
� angina pectoris requiring medication
� clinically significant valvular disease
� evidence of transmural infarction on electrocardiograph (ECG)
� poorly controlled hypertension.

1.3 Cardiac functional assessments should be repeated every 3 months during trastuzumab treatment. If the LVEF drops by 10% from baseline and to below 50% then trastuzumab treatment should be suspended. A decision to resume trastuzumab therapy should be based on a further cardiac assessment and a fully informed discussion of the risks and benefits between the individual patient and their clinician.

The National Institute for Health and Clinical Excellence (NICE) is the independent organisation responsible for providing national guidance on the promotion of good health and the prevention and treatment of ill health. NICE produces guidance in three areas of health: public health guidance on the promotion of good health and the prevention of ill health for those working in the NHS, local authorities and the wider public and voluntary sector; health technologies guidance on the use of new and existing medicines, treatments and procedures within the NHS; and clinical practice guidance on the appropriate treatment and care of people with specific diseases and conditions within the NHS. NICE issues guidance on the clinical and cost effectiveness of selected new and existing drugs for the NHS in England and Wales. It does this after new medicines have been licensed by the Medicines and Healthcare products Regulatory Agency/European Medicines Evaluation Agency.
 

- National Institute for Health and Clinical Excellence (NICE)
 

www.nice.org.uk

 
Subscribe to UK Newsletter
E-mail Address:

 

NICE has introducing a new, rapid process to enable faster guidance on life-saving drugs which have already been licensed and on new medicines close to when they first become available. Details can be found on the NICE website.

Related UK News

Indians among worst affected by TB in Britain
Mental health units should not be exempt from smoking ban
NHS may be buying surgical equipment unethically
Is it time to give NHS more independence?
University of Leeds receives Gates Foundation grant for material approach to malaria prevention
Tuberculosis control and impact of socially excluded groups
Pertussis Endemic Among UK School Children
Building a safer NHS: How safe are the patients?
Experts Comment on New Blood Pressure Guidelines
New Guideance will Result in Better Control of Hypertension - BPA


For any corrections of factual information, to contact the editors or to send any medical news or health news press releases, use feedback form

Top of Page

 

© Copyright 2004 onwards by RxPG Medical Solutions Private Limited
Contact Us